ANXA1 (Annexin A1)
A multifunctional calcium-dependent phospholipid-binding protein involved in anti-inflammatory signaling, cell proliferation, and apoptosis.
Gene Information Card
| Symbol | ANXA1 |
|---|---|
| Full Name | Annexin A1 |
| Gene Type | Protein coding |
| Chromosomal Location | 9q21.13 |
| NCBI Gene ID | 301 ncbi.nlm.nih.gov/gene/301 |
| Ensembl ID | ENSG00000135046 |
| UniProt ID | P04083 |
| OMIM ID | 151690 |
| HGNC ID | 533 |
| Aliases | ANX1, LPC1, lipocortin 1, calpactin II, chromobindin-9, p35 |
Description
ANXA1 (annexin A1) encodes a calcium-dependent phospholipid-binding protein that belongs to the annexin family. It plays key roles in anti-inflammatory signaling, glucocorticoid-mediated responses, cell proliferation, differentiation, and apoptosis. The protein is a substrate for epidermal growth factor receptor (EGFR) and protein kinase C (PKC). ANXA1 is involved in membrane aggregation, exocytosis, and regulation of cell growth.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Dysregulated expression affects cell proliferation, invasion, and metastasis; may act as tumor suppressor or promoter depending on context. | Multiple studies in NCBI PubMed; COSMIC database reports mutations in several cancer types. |
| Inflammatory disorders | Anti-inflammatory effects via inhibition of phospholipase A2 and modulation of immune cell migration. | ClinVar and OMIM entries; experimental evidence from animal models. |
| Cardiovascular disease | Modulates vascular inflammation and atherosclerosis progression. | NCBI Gene and UniProt annotations. |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 31.2 | High |
| Spleen | 28.5 | High |
| Bone marrow | 25.1 | High |
| Colon | 18.7 | Medium |
| Breast | 12.3 | Medium |
| Liver | 8.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 45.2 | Cervical cancer cell line; high expression |
| A549 | 38.7 | Lung adenocarcinoma cell line; high expression |
| MCF7 | 22.1 | Breast cancer cell line; moderate expression |
| K562 | 15.6 | Leukemia cell line; moderate expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.184G>A (p.Gly62Ser) | Missense | Rare | Unknown functional impact; reported in COSMIC |
| c.427C>T (p.Arg143Trp) | Missense | Rare | Potential loss of calcium binding; COSMIC |
| c.739G>A (p.Gly247Arg) | Missense | Rare | Reported in cancer samples; functional significance unclear |
Mutation functional classification
Loss of Function (LOF)
Missense mutations in calcium-binding domains may impair phospholipid binding and anti-inflammatory activity.
Gain of Function (GOF)
Not well characterized; overexpression in some cancers suggests possible oncogenic role.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • GO:0005509 – calcium ion binding | • GO:0005544 – calcium-dependent phospholipid binding |
| • GO:0042802 – identical protein binding | • GO:0008284 – positive regulation of cell population proliferation |
| • GO:0043066 – negative regulation of apoptotic process | • GO:0050729 – positive regulation of inflammatory response |
Pathways
• Glucocorticoid receptor pathway
• EGFR signaling pathway
• Phospholipase A2 inhibition pathway
• Annexin pathway
Protein Summary
Annexin A1 is a 37 kDa protein composed of four annexin repeats, each containing a calcium-binding site. It is predominantly cytosolic but translocates to the plasma membrane upon calcium elevation. The N-terminal domain mediates interactions with S100 proteins and other partners. Post-translational modifications include phosphorylation by EGFR and PKC, and proteolytic cleavage by matrix metalloproteinases. ANXA1 is secreted and acts extracellularly via formyl peptide receptors (FPRs) to exert anti-inflammatory effects.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ANXA13 Knockout HEK293 Cell Line | EDJ-KQ3389 | Human | 312 | Details Get a Quote |
| ANXA1 Knockout HEK293 Cell Line | EDJ-KQ3691 | Human | 301 | Details Get a Quote |
| ANXA11 Knockout HEK293 Cell Line | EDJ-KQ4058 | Human | 311 | Details Get a Quote |
| ANXA10 Knockout HEK293 Cell Line | EDJ-KQ6691 | Human | 11199 | Details Get a Quote |
| ANXA1 Knockout A-549 Cell Line | EDJ-KQ25692 | Human | 301 | Details Get a Quote |
| ANXA1 Knockout HCT 116 Cell Line | EDJ-KQ25693 | Human | 301 | Details Get a Quote |
| ANXA1 Knockout HeLa Cell Line | EDJ-KQ25694 | Human | 301 | Details Get a Quote |
| ANXA13 Knockout A-549 Cell Line | EDJ-KQ26417 | Human | 312 | Details Get a Quote |
| ANXA11 Knockout A-549 Cell Line | EDJ-KQ26421 | Human | 311 | Details Get a Quote |
| ANXA11 Knockout HCT 116 Cell Line | EDJ-KQ26422 | Human | 311 | Details Get a Quote |
| ANXA11 Knockout HeLa Cell Line | EDJ-KQ26423 | Human | 311 | Details Get a Quote |
| ANXA10 Knockout HCT 116 Cell Line | EDJ-KQ32410 | Human | 11199 | Details Get a Quote |
| ANXA10 Knockout HeLa Cell Line | EDJ-KQ32411 | Human | 11199 | Details Get a Quote |
| SPANXA1 Knockout HEK293 Cell Line | EDJ-KQ51253 | Human | 30014 | Details Get a Quote |
| ANXA13 Knockout HeLa Cell Line | EDJ-KQ52621 | Human | 312 | Details Get a Quote |
Displaying Records 1 To 15 Of 21 Records
